Combination of carbapenem antibiotics with relebactam on carbapenemase-producing Enterobacteriaceae
Abstract
Carbapenemase-producing Enterobacteriaceae have spread throughout the world, causing infections of high mortality and morbility. Carbapenem antibiotics are used as a last option against serious infections caused by these bacteria, due to the few adverse effects and low toxicity. However, their continuous use has given rise to a resistence phenomena such as the production of carbapenemase enzymes and has led to the search for combinations of these beta-lactam antibiotics with carbapenemase inhibitors, to help combat this public health problem. In this work, information was collected between 2015 and 2023, to get better understanding of the frequency of different carbapenemases produced by Enterobacteriaceae found in Spain and the activity of relebactam inhibitor in combination with carbapenems against these bacteria. In Spain, Klebsiella pneumoniae was the most frequent carbapenem-producing Enterobacteriaceae (73.8 %) and KPC, the most common carbapenemase (45.11 %), when compared to OXA-48 (42.29 %), VIM (13.23 %) and NDM (3.47 %). The addition of relebactam restores almost 100% activity of imipenem against KPC-producing Enterobacteriaceae. KPC-producing Escherichia coli and K. pneumoniae are inhibited by the combination of ertapenem and relebactam. Relebactam restores the activity of imipenem and ertapenem against KPC-producing Enterobacteriaceae.
Keywords: carbapenemases, relebactam, beta-lactamase inhibitor, carbapenemsDownloads
References
Lorenzo P, Moreno A, Leza JC, Lizasoain I, Moro MA, Portolés Velázquez A. Farmacología Básica y Clínica. Buenos Aires: Editorial Médica Panamericana S.A;2018.
Prats G. Microbiología y Parasitología Médica. Buenos Aires : Editorial Médica ;2019.
Ciftci E, Cetin E, Us E, Kutlu HH, Aridogan BC. Investigation of Carbapenem resistance mechanisms in Klebsiella pneumoniae by using phenotypic tests and a molecular assay. J Infect Dev Ctries. 2019;13(11):992–1000.
Queenan AM, Bush K. Carbapenemases: The versatile β-lactamases. Clin Microbiol Rev. 2007;20(3):440–58.
Blázquez Garrido RS, Cuchí Burgos E, Martín Salas C, Ruiz-Garbajosa P. Métodos microbiológicos para la monitorización de la limpieza, desinfección y esterilización de
dispositivos médicos .En: Procedimientos en microbiología clínica.España:SEIMC; 2006 Available from: https://acici.cat/wp-content/uploads/2023/05/seimc-procedimientomicrobiologia.pdf
Goodman KE, Simner PJ, Tamma PD, Milstone AM. Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE). Expert Rev Anti Infect Ther [Internet]. 2016 [citado 18 feb 2025];14(1):95–108. Available from: https://www.tandfonline.com/doi/full/10.1586/14787210.2016.1106940
Li J, Yu T, Tao XY, Hu YM, Wang HC, Liu JL, et al. Emergence of an NDM-5-producing Escherichia coli sequence type 410 clone in infants in a children’s hospital in China. Infect Drug Resist. 2020;13:703–10.
Liu J, Zhang L, Pan J, Huang M, Li Y, Zhang H, et al. Risk Factors and Molecular Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant Enterobacteriaceae: A Multicenter Study in China. J Infect Dis. 2020;221(2):S156–63.
Tayh G, Nagarjuna D, Sallem R Ben, Verma V, Chairat S, Boudabous A, et al. First report of vim metallo-β-lactamase production in escherichia coli and klebsiella pneumoniae clinical isolates from gaza strip, palestine. Germs. 2020;10(1):18–26.
Galani I, Nafplioti K, Chatzikonstantinou M, Souli M. In vitro evaluation of double-carbapenem combinations against oxa-48-producing Klebsiella pneumoniae isolates using time-kill studies. J Med Microbiol. 2018;67(5):662–8.
Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018;8(JAN):1–15.
Oteo J, Calbo E, Rodríguez-ba J, Ruiz-garbajosa P, Horcajada JP, Luis J, et al. La amenaza de las enterobacterias productoras de carbapenemasas ˜ documento de posicionamiento de los grupos de estudio en Espana : GEIH y GEMARA de la SEIMC. 2014;32(10):666–70.
Tórtola MT, Lavilla S, Miró E, González JJ, Larrosa N, Sabaté M, et al. First detection of a carbapenem-hydrolyzing metalloenzyme in two Enterobacteriaceae isolates in Spain. Antimicrob Agents Chemother. 2005;49(8):3492–4.
Noval M, Banoub M, Claeys KC, Heil E. The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. Curr Infect Dis Rep. 2020;22(1):1–9.
J. Nicholas O’Donnell a TPL aDepartment. New Perspectives on Antimicrobial Agents: Maribavir. New Perspect Antimicrob Agents Imipenem- Relebactam. 2022;66(9):1–19.
Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. 2018;78(1):65–98.
Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J. 2011;104(1):40–5.
Hafi El, Rasheed SS, Abou Fayad AG, Araj GF, Matar GM. Evaluating the efficacies of carbapenem/β-lactamase inhibitors against carbapenem-resistant gram-negative bacteria in vitro and in vivo. Front Microbiol. 2019;10(APR):1–13.
Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, et al. Relebactam is a potent inhibitor of the kpc-2 -lactamase and restores imipenem susceptibility in kpc-producing enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(6):1–9.
Fuster B, Tormo N, Salvador C, Gimeno C. Detection of two simultaneous outbreaks of Klebsiella pneumoniae coproducing OXA-48 and NDM-1 carbapenemases in a tertiary-care hospital in Valencia, Spain. New Microbes New Infect [Internet]. 2020[citado 18 feb 2025];34:100660. Available from: https://www.sciencedirect.com/science/article/pii/S2052297520300123
Soria-Segarra C, González-Bustos P, López-Cerero L, Fernández-Cuenca F, Rojo-Martín MD, Fernández-Sierra MA, et al. Tracking KPC-3-producing ST-258 Klebsiella pneumoniae outbreak in a third-level hospital in Granada (Andalusia, Spain) by risk factors and molecular characteristics. Mol Biol Rep [Internet]. 2020[citado 18 feb 2025];47(2):1089–97. Available from: https://pubmed.ncbi.nlm.nih.gov/31792747/
Lalaoui R, Djukovic A, Bakour S, Hadjadj L, Sanz J, Salavert M, et al. Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain. Antimicrob Resist Infect Control. 2019;8(1):4–9.
López-González L, Viñuela-Prieto JM, Rodriguez-Avial I, Manzano R, Candel FJ. Description of carbapenemase-producing enterobacteriaceae isolates in a Spanish tertiary hospital. Epidemiological analysis and clinical impact. Rev Esp Quimioter. 2019;32(3):254–62.
López-Hernández I, García Barrionuevo A, Díaz de Alba P, Clavijo E, Pascual A. Characterization of NDM-1- and CMH-3-producing Enterobacter cloacae complex ST932 in a patient transferred from Ukraine to Spain. Enferm Infecc Microbiol Clin [Internet]. 2019;(xx). Available from:
Hernández-García M, León-Sampedro R, Pérez-Viso B, Morosini MI, López-Fresneña N, Diaz-Agero C, et.al. First Report of an OXA-48- and CTX-M-213-Producing Kluyvera Species Clone Recovered from Patients Admitted in a University Hospital in Madrid, Spain. 2018;62(11):1–10
Johnston BD, Thuras P, Porter SB, Anacker M, VonBank B, Vagnone PS, et al. Activity of imipenem-relebactam against carbapenem-resistant Escherichia coli isolates from the United States in relation to clonal background, resistance genes, coresistance, and region. Antimicrob Agents Chemother. 2020;64(5):1–23
Karlowsky J, Lob S, Raddatz J, DePestel D, Young K, Motyl M, Sahm D. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam against Clinical Isolates of Gram-Negative Bacilli with Difficult-to-Treat Resistance and Multidrug Resistant Phenotypes – SMART United States 2015-2017. Infect Dis Soc Am. 2020;53(9):1689–99
Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, et al. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017. J Med Microbiol. 2020;69(2):207–17
Canver M, Satlin M, Westblade L, Kreiswirth B, Chen L, Robertson A, et.al. Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(9):1–5
Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2016;17(2):153–63
ECDC. Surveillance Atlas of Infectious Diseases [Internet]. 2020. Available from: https://atlas.ecdc.europa.eu/public/index.aspx
Sánchez-López J, Cantón R. Current status of ESKAPE microorganisms in Spain: Epidemiology and resistance phenotypes. Rev Esp Quimioter. 2019;32:27–31
Woodford N, Dallow JWT, Hill RLR, Palepou MFI, Pike R, Ward ME, et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents. 2007;29(4):456–9
Ding L, Shen S, Chen J, Tian Z, Shi Q, Han R, et al. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clin Microbiol Rev. 2023;36(4)
López-diaz MC, Culebras E, Rodríguez-avial I, Rios E, Viñuela-prieto JM, Picazo JJ. crossm Modifying Enzymes. 2017;61(2):1–4
Oteo J, Pérez-Vázquez M, Bautista V, Ortega A, Zamarrón P, Saez D, et al. The spread of KPC-producing Enterobacteriaceae in Spain: WGS analysis of the emerging high-risk clones of Klebsiella pneumoniae ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. J Antimicrob Chemother. 2016;71(12):3392–9
Published
How to Cite
Issue
Section
License
ACCESS AND DISTRIBUTION POLICY
All published articles are open access contributions, which are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is properly cited.
